Douglas F. Roth, MM, MA, CCC-SLP

Director, Voice Pathology; Associate Director, BWH Voice Program
Brigham and Women's Hospital, Division of Otolaryngology
Boston, MA, United States

Douglas Roth, MM, MA, CCC-SLP is the Director of Voice Pathology and Associate Director of the Voice Program at Brigham and Women’s Hospital. He began his career as a classical singer before becoming a speech-language pathologist. He specializes in adult and pediatric voice disorders, care of the professional voice, upper airway breathing disorders, swallowing disorders, head and neck cancer and alaryngeal voice rehabilitation. He has guided the vocal rehabilitation of singers in various genres ranging from classical, musical theater and jazz to hard rock. These have included professional singers from regional and touring musical theatre companies, professional opera houses, and international touring rock bands. As a teacher of singing and vocal pedagogue, he is frequently invited to give vocal master classes at the university level and to present on vocal health, singer’s wellness and vocal pedagogy. His research interests focus on the effects of allergies on the voice, therapy efficacy and how people learn skilled vocal behaviors. In particular, he is interested in how instructions, feedback and directed attention should best be implemented to facilitate maximal and expedited learning for both vocal rehabilitation and singing instruction. He has presented nationally and internationally on medical speech-language pathology and on the application of motor learning principles and skill transfer in vocal rehabilitation and singing instruction. He holds degrees in vocal performance from the University of Cincinnati College-Conservatory of Music and Arizona State University and a master’s degree in speech pathology from Indiana University.

Presentation(s):

• Chronic Cough: Hacking Up Better Solutions

  Tuesday, October 1, 2024
  12:30 PM – 1:30 PM EDT

  Disclosure(s):

  faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.